MovDisordV3, PubMed, Corpus, bibRecord, 001911

Carisbamate in essential tremor: brief report of a proof of concept study.

Identifieur interne : 001911 ( PubMed/Corpus ); précédent : 001910; suivant : 001912

Carisbamate in essential tremor: brief report of a proof of concept study.

Auteurs : Rodger J. Elble ; David M. Biondi ; Steve Ascher ; Frank Wiegand ; Joseph Hulihan

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.

RBID : pubmed:20201005

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Anticonvulsants (therapeutic use), Carbamates (therapeutic use), Cross-Over Studies, Double-Blind Method, Essential Tremor (drug therapy), Female, Humans, Male, Middle Aged, Severity of Illness Index, Young Adult.
MESH :
- chemical , therapeutic use : Anticonvulsants, Carbamates.
- drug therapy : Essential Tremor.
- Adolescent, Adult, Aged, Aged, 80 and over, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Severity of Illness Index, Young Adult.

Abstract

The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo.

DOI: 10.1002/mds.22872
PubMed: 20201005

Links to Exploration step

pubmed:20201005

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carisbamate in essential tremor: brief report of a proof of concept study.</title>
<author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J" last="Elble">Rodger J. Elble</name>
<affiliation><nlm:affiliation>Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. relble@siumed.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Biondi, David M" sort="Biondi, David M" uniqKey="Biondi D" first="David M" last="Biondi">David M. Biondi</name>
</author>
<author><name sortKey="Ascher, Steve" sort="Ascher, Steve" uniqKey="Ascher S" first="Steve" last="Ascher">Steve Ascher</name>
</author>
<author><name sortKey="Wiegand, Frank" sort="Wiegand, Frank" uniqKey="Wiegand F" first="Frank" last="Wiegand">Frank Wiegand</name>
</author>
<author><name sortKey="Hulihan, Joseph" sort="Hulihan, Joseph" uniqKey="Hulihan J" first="Joseph" last="Hulihan">Joseph Hulihan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.22872</idno>
<idno type="RBID">pubmed:20201005</idno>
<idno type="pmid">20201005</idno>
<idno type="wicri:Area/PubMed/Corpus">001911</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Carisbamate in essential tremor: brief report of a proof of concept study.</title>
<author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J" last="Elble">Rodger J. Elble</name>
<affiliation><nlm:affiliation>Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. relble@siumed.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Biondi, David M" sort="Biondi, David M" uniqKey="Biondi D" first="David M" last="Biondi">David M. Biondi</name>
</author>
<author><name sortKey="Ascher, Steve" sort="Ascher, Steve" uniqKey="Ascher S" first="Steve" last="Ascher">Steve Ascher</name>
</author>
<author><name sortKey="Wiegand, Frank" sort="Wiegand, Frank" uniqKey="Wiegand F" first="Frank" last="Wiegand">Frank Wiegand</name>
</author>
<author><name sortKey="Hulihan, Joseph" sort="Hulihan, Joseph" uniqKey="Hulihan J" first="Joseph" last="Hulihan">Joseph Hulihan</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Anticonvulsants (therapeutic use)</term>
<term>Carbamates (therapeutic use)</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Essential Tremor (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term>
<term>Carbamates</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20201005</PMID>
<DateCreated><Year>2010</Year>
<Month>04</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>07</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>5</Issue>
<PubDate><Year>2010</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Carisbamate in essential tremor: brief report of a proof of concept study.</ArticleTitle>
<Pagination><MedlinePgn>634-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22872</ELocationID>
<Abstract><AbstractText>The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo.</AbstractText>
<CopyrightInformation>(c) 2010 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elble</LastName>
<ForeName>Rodger J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo><Affiliation>Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. relble@siumed.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Biondi</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ascher</LastName>
<ForeName>Steve</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wiegand</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hulihan</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00524056</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C518914">S-2-O-carbamoyl-1-o-chlorophenyl-ethanol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002219">Carbamates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020329">Essential Tremor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>7</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.22872</ArticleId>
<ArticleId IdType="pubmed">20201005</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001911 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001911 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:20201005
   |texte=   Carisbamate in essential tremor: brief report of a proof of concept study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:20201005" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Carisbamate in essential tremor: brief report of a proof of concept study.

Carisbamate in essential tremor: brief report of a proof of concept study.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki